Source: Clinical science. Unidade: FM
Subjects: TROMBOSE, CONTENEDORES, FÁRMACOS IMUNOSSUPRESSORES, SISTEMA IMUNE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MIYAKAWA, Ayumi A. et al. Rapamycin activates TGF receptor independently of its ligand: implications for endothelial dysfunction. Clinical science, v. 132, n. 4, p. 437-447, 2018Tradução . . Disponível em: https://doi.org/10.1042/CS20171457. Acesso em: 13 out. 2024.APA
Miyakawa, A. A., Girao-Silva, T., Krieger, J. E., & Eelmann, E. R. (2018). Rapamycin activates TGF receptor independently of its ligand: implications for endothelial dysfunction. Clinical science, 132( 4), 437-447. doi:10.1042/CS20171457NLM
Miyakawa AA, Girao-Silva T, Krieger JE, Eelmann ER. Rapamycin activates TGF receptor independently of its ligand: implications for endothelial dysfunction [Internet]. Clinical science. 2018 ; 132( 4): 437-447.[citado 2024 out. 13 ] Available from: https://doi.org/10.1042/CS20171457Vancouver
Miyakawa AA, Girao-Silva T, Krieger JE, Eelmann ER. Rapamycin activates TGF receptor independently of its ligand: implications for endothelial dysfunction [Internet]. Clinical science. 2018 ; 132( 4): 437-447.[citado 2024 out. 13 ] Available from: https://doi.org/10.1042/CS20171457
